肠道微生物群和肝硬化之间的因果关系:16S rRNA测序和门德尔随机化分析
Mengqin Yuan1, Xue Hu1, Lichao Yao1
1Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Journal of clinical and translational hepatology
|February 12, 2024
概括
这项研究揭示了肠道细菌和肝硬化之间的因果关系. 特定的细菌,如Butyricicoccus和Marvinbryantia可能会防止肝硬化风险.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 遗传学 是一个遗传学.
背景情况:
- 人们越来越多地认识到肠道微生物群在肝硬化中的作用,但尚未完全理解.
- 现有证据表明,肠道微生物组成和肝硬化发展之间存在强烈的关联.
研究的目的:
- 调查肠道微生物群和肝硬化之间的因果关系.
- 为了确定与肝硬化风险相关的特定细菌种群.
主要方法:
- 16S rRNA测序用于分析诱导肝硬化和对照小鼠中的细菌群体.
- 两个样本的门德尔随机化 (MR) 分析以推断因果关系.
- 用人类肝硬化患者的便样本和健康对照进行验证.
主要成果:
- 在肝炎和对照小鼠之间观察到肠道微生物群组成的显著差异.
- 门德尔随机分析发现了潜在的因果关系,其中Butyricicoccus和Marvinbryantia显示出与肝硬化风险的稳定负相关性.
- 人类样本验证证实,与肝硬化患者相比,健康对照组中*Butyricicoccus*和*Marvinbryantia*的相对丰度较高.
结论:
- 这项研究为肠道微生物群参与肝硬化提供了新的因果证据.
- 研究结果表明,特定的肠道细菌,如*Butyricicoccus*和*Marvinbryantia*,可能起着保护作用.
- 这些见解可以为开发预防肝硬化新策略提供信息.
相关概念视频
Introduction to the Human Microbiota
Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity, and disease...
Dysbiosis of the Gut Microbiota
The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...


